Literature DB >> 27863359

Is hyperhomocysteinemia a causal factor for heart failure? The impact of the functional variants of MTHFR and PON1 on ischemic and non-ischemic etiology.

Ewa Strauss1, Wieslaw Supinski2, Artur Radziemski3, Grzegorz Oszkinis4, Andrzej Leon Pawlak5, Jerzy Gluszek6.   

Abstract

BACKGROUND: Hyperhomocysteinemia was found to be uniformly associated with the development of heart failure (HF) and HF mortality; however, it is uncertain whether this relation is causative or not. We used Mendelian randomization to examine the associations of the methylene tetrahydrofolate gene (MTHFR) and paraoxonase 1 gene (PON1) variants as a proxy for lifelong exposure to high Hcy and Hcy-thiolactone concentrations with the development of HF in men aged ≤60years and the occurrence of adverse effects at one-year follow-up.
METHODS: The study enrolled 172 men with HF: 117 with ischemic etiology (iHF) related to coronary artery disease (CAD) and 55 with non-ischemic etiology (niHF) related to dilated cardiomyopathy (DCM). The reference group of 329 CAD patients without HF and the control group of 384 men were also analyzed.
RESULTS: Hyperhomocysteinemia (OR=2.0, P<0.05) and the MTHFR 677TT/1298AA, 677CC/1298CC genotypes (OR=1.6, P=0.03) were associated with HF regardless of its etiology, especially among normotensives (OR=4.6, P=0.001 and OR=2.3, P=0.003, respectively). In niHF, the PON1 162AA (OR=2.3, P=0.03) and 575AG+GG (OR=0.46, P=0.01) genotypes also influenced the risk. The interaction between HDLC<1mmol/L and the PON1 575GG genotype was found to influence the risk of iHF (OR=7.2, P=0.009). Hyperhomocysteinemia improved the classification of niHF patients as 'high-risk' by 10.1%. Ejection fraction <30% and DCM increased the probability of HF death or re-hospitalization within one year.
CONCLUSION: Our results provide evidence that hyperhomocysteinemia is a causal factor for niHF in DCM, while dysfunctional HDL could contribute to the pathogenesis of iHF.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Ejection fraction; Heart failure; Homocysteine; MTHFR; PON1

Mesh:

Substances:

Year:  2016        PMID: 27863359     DOI: 10.1016/j.ijcard.2016.11.213

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Point-of-Care Ultrasonography Saves the Day in Dilated Cardiomyopathy: A Rare Presentation of Hyperhomocysteinemia.

Authors:  Mack Sheraton; Dhaval Patel; Richard Houck
Journal:  Cureus       Date:  2021-07-28

Review 2.  Metabolic Therapy of Heart Failure: Is There a Future for B Vitamins?

Authors:  Jérôme Piquereau; Solène E Boitard; Renée Ventura-Clapier; Mathias Mericskay
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

3.  MiR-483-3p improves learning and memory abilities via XPO1 in Alzheimer's disease.

Authors:  Gang Luo; Xiaoyan Wang; Changya Liu
Journal:  Brain Behav       Date:  2022-07-14       Impact factor: 3.405

Review 4.  Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems.

Authors:  Peter Kaplan; Zuzana Tatarkova; Monika Kmetova Sivonova; Peter Racay; Jan Lehotsky
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.